Today, Oppenheimer initiated coverage on ACST stock with an “outperform” rating and a price target of $6. Even after today’s significant price increase, the price target still represents upside of ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Acasti Pharma (ACST) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Acasti Pharma (NASDAQ:ACST) just reported results for the first quarter of 2025. Acasti Pharma reported earnings per share of -24 cents. This was above the analyst estimate for EPS of -25 cents. The ...

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...

At close: 4:08:14 pm GMT+7 ...